Canadian Prime Minister Justin Trudeau has announced that Covid-19 vaccine developer Moderna will build a manufacturing facility in the country's Quebec to deliver up to 100 million mRNA vaccine doses annually.
Construction is set to start this year and the facility is expected to be operational in 2024 at the earliest, subject to planning and regulatory approvals, Trudeau said on Friday in a press release.
In addition to Covid-19 vaccines, the facility is expected to be able to produce vaccines for other respiratory diseases such as influenza, pending the ongoing development by Moderna and approval by Health Canada, according to the news release.
"Covid-19 vaccines saved lives and got Canadians back to doing the things they love," the Prime Minister added.
Canadian Health Minister, Jean-Yves Duclos said the government will build a domestic biomanufacturing capacity to ensure that Canada continues to have access to vaccines well into the future, Xinhua news agency reported.
Health Canada authorised Moderna's Spikevax vaccine for adults in December 2020, teenagers in August 2021 and for children aged between six to 11 years in March 2022. More than 29 million doses of Spikevax vaccine have been distributed across Canada.
The company is applying for a vaccine to protect children between six months and five-years-old in Canada. Currently there is no vaccine authorised for children younger than five years.
--IANS
int/khz/
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)